Article
Medicine, Research & Experimental
Hui Xu, Fengshu Zhao, Di Wu, Yunxia Zhang, Xueyang Bao, Fangfang Shi, Yunlang Cai, Jun Dou
Summary: The immune effects of cancer stem cells (CSCs) vaccines on ovarian cancer (OC) were evaluated. The CSC vaccines were capable of significantly provoking immune responses to autologous tumor antigens in vaccinated mice, resulting in inhibited tumor growth, prolonged survival, and decreased CSC counts in OC tissues. The antitumor efficacy of the vaccines was reduced when the mucin-1 expression in CSC vaccines was down-regulated.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Article
Oncology
Shannon Lange, Laurens G. L. Sand, Matthew Bell, Sagar L. Patil, Deanna Langfitt, Stephen Gottschalk
Summary: We designed a chimeric cytokine receptor (GM18) that links CAR T-cell activation to MyD88 signaling. GM18 endows CAR T cells with sustained effector function in the setting of chronic antigen exposure, resulting in potent antitumor activity in preclinical solid tumor models.
Review
Immunology
Xi Zhang, Tianhui He, Yuan Li, Ling Chen, Hongyu Liu, Yu Wu, Hongyan Guo
Summary: Ovarian cancer is characterized by uncertain presentation and poor outcomes, with surgery and chemotherapy being the current basis of treatment. However, there are limitations due to advanced stage at diagnosis and high recurrence rate. The use of anti-VEGF agents, PARP inhibitors, and immunotherapies are being explored to enhance treatment outcomes, but the population that can benefit from these treatments remains limited.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Immunology
Ping Yu, Yaru Wang, Dahai Yuan, Yunqin Sun, Shuang Qin, Tianye Li
Summary: The review provides a comprehensive overview of vascular normalization and its potential implications in ovarian cancer. The evidence suggests that vascular normalization therapy is a promising approach that can modify the tumor microenvironment, enhance anti-tumor immunity, and synergize with immunotherapy. This review contributes to the growing body of knowledge supporting the utilization of combination therapy as a promising treatment paradigm for ovarian cancer.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Qiushi Tang, Shuo Yang, Guangpeng He, Hongyu Zheng, Sheng Zhang, Jiaxing Liu, Shibo Wei, Qing Fan, Xueqiang Peng, Xinyu Li, Dewei Zhang, Liang Yang, Hangyu Li
Summary: Tumor-derived exosomes (TDEs) play a critical role in regulating the immune microenvironment of tumors and have the ability to suppress immune responses, thus impacting the effectiveness of cancer therapy. By delivering suppressive factors to immune cells, TDEs directly or indirectly influence immune cell function and antitumor activities. TDE-based therapy is emerging as a promising strategy for inhibiting tumor progression and enhancing antitumor immunity.
Review
Nutrition & Dietetics
Bo Li, Lili Yang
Summary: Creatine is widely used as a dietary supplement with known benefits on the musculoskeletal system, but its metabolic regulation beyond muscle cells is not well understood. Recent research highlights the diverse regulatory functions of creatine in various physiological systems, especially its role in enhancing T cell antitumor immunity. Creatine supplementation has been shown to boost antitumor T cell immunity and synergize with other cancer immunotherapy modalities to improve antitumor efficacy.
Article
Cell Biology
Silvana Opp, Alicia Hurtado, Christine Pampeno, Ziyan Lin, Daniel Meruelo
Summary: Our laboratory has developed a Sindbis viral (SV) vector platform for ovarian and other types of cancers treatment. We found that SV.IL-12 combined with OX40 antibody can effectively eliminate ovarian cancer in a mouse model and prevent tumor growth in mice rechallenged with tumor cells after 5 months. T-cell reprogramming and immune cell infiltration contribute to the treatment efficacy. The combination of IL-12 and anti-OX40 sequences in a single SV vector facilitates the delivery of immunoregulatory agents, enhancing the anti-tumor response. We propose SV.IgGOX40.IL-12 as a safe and effective therapy for multiple types of cancer.
Article
Oncology
Erkko Ylosmaki, Manlio Fusciello, Beatriz Martins, Sara Feola, Firas Hamdan, Jacopo Chiaro, Leena Ylosmaki, Matthew J. Vaughan, Tapani Viitala, Prasad S. Kulkarni, Vincenzo Cerullo
Summary: The study developed a novel cancer vaccine platform based on BCG, which can broaden immune responses to include tumor antigens. Coating BCG with tumor-specific peptides improved antitumor immune responses and increased the number of responders to anti-PD-1 immunotherapy when combined with ICI therapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Engineering, Biomedical
Meiling Jin, Jingchu Hu, Lili Tong, Bao-Zhong Zhang, Jian-Dong Huang
Summary: Embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) show similarities with cancer cells and can be used as effective vaccines against cancer in animal models. The molecular basis of this effect is not well understood, but the development of bladder cancer vaccines using ESCs has shown promising results by stimulating specific antitumor immunity and reducing cancer growth. Overexpressed genes in both ESCs and tumors have been identified, and a vaccine designed based on shared overexpressed proteins has been shown to induce specific antitumor immunity and reduce bladder cancer growth. This study provides a systematic approach for the development of effective epitope-based cancer vaccines in the future.
ADVANCED HEALTHCARE MATERIALS
(2023)
Review
Oncology
Razan Alzeibak, Tatiana A. Mishchenko, Natalia Y. Shilyagina, Irina V. Balalaeva, Maria V. Vedunova, Dmitri V. Krysko
Summary: The past decade has seen significant breakthroughs in cancer immunotherapy, with immunogenic cell death (ICD) emerging as a promising approach to eliminate tumor cells. Photodynamic therapy (PDT) can induce ICD, but its efficiency is reduced in hypoxic tumor environments. Future research may focus on strategies like oxygen-boosted PDT and nanotechnology to address this limitation.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Review
Immunology
Junfeng Zhang, Feifei Lei, Huabing Tan
Summary: CD8(+) T cells play a critical role in antitumor immunotherapy, but during chronic infection or tumorigenesis, these cells often become dysfunctional, exhibiting a state known as T-cell exhaustion (Tex). In this state, the expression of inhibitory checkpoint receptors increases, and interventions targeting immune checkpoint blockades (ICBs) have been considered a promising strategy. Recent investigations have shown that exhausted T cells exhibit differences in function, metabolism, transcription, and epigenetics, and comprise a heterogeneous group of cells. In this review, we summarize the current findings on the dynamic differentiation process of Tex heterogeneity development in cancer and chronic infection. We discuss how the responses to immunotherapy are determined by these distinct subsets and highlight prospective approaches for improving the efficacy of ICB therapy for cancer by leveraging the heterogeneity of T cells.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Chemistry, Multidisciplinary
Long Xiao, Yu Huang, Yuhe Yang, Zhiwei Miao, Jie Zhu, Mengdan Zhong, Chencheng Feng, Wenkai Tang, Jinhua Zhou, Lihong Wang, Xin Zhao, Zhirong Wang
Summary: The researchers have developed a biomimetic cytomembrane cancer nanovaccine named CCMP@R837, which enhanced the immune response against breast cancer cells and established immune memory in BALB/c mice. This vaccine platform shows potential as a candidate for preventive cancer vaccines in clinical settings.
Article
Oncology
Antonella Vardeu, Charlotte Davis, Ian McDonald, Guilherme Stahlberg, Barsha Thapa, Kinga Piotrowska, Margaret A. Marshall, Thomas Evans, Vicky Wheeler, Sarah Sebastian, Katie Anderson
Summary: The use of immunotherapeutic vaccination in prostate cancer is a promising approach. The experimental approach described here uses a well-studied adenovirus-poxvirus heterologous prime-boost regimen, which can induce functional cytotoxic T cells.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Review
Chemistry, Multidisciplinary
Wen-Hao Li, Jing-Yun Su, Yan-Mei Li
Summary: Cancer vaccines aim to enhance tumor-specific immune responses by engaging both T-cell and B-cell immunity. Different factors, including antigen selection, immune activation, vaccine delivery, and repeatable vaccination, should be considered for the rational design of therapeutic cancer vaccines. Chemical strategies such as adjuvants and nanomaterials play crucial roles in advancing the development of effective T-cell- and B-cell-based cancer vaccines.
ACCOUNTS OF CHEMICAL RESEARCH
(2022)
Review
Oncology
Noor Shakfa, Deyang Li, Sarah Nersesian, Juliette Wilson-Sanchez, Madhuri Koti
Summary: Ovarian cancer, particularly high-grade serous ovarian carcinoma, is resistant to conventional therapies. Studies have shown that tumors with DNA damage repair gene deficiency and chromosomal instability have increased immune cell infiltration and expression of immune-related genes. However, most ovarian cancer patients have not responded to immunomodulatory treatments due to the lack of understanding of the mechanisms underlying immune infiltration.
BRITISH JOURNAL OF CANCER
(2022)
